Le Lézard
Classified in: Health
Subjects: PDT, MAT

The People's Ecosystem Launches Toci Treats Powered by Unlokttm in New Mexico


Safer, More Predictable Edibles by Legacy BIPOC Women Use Pharma-Grade Delivery System and Give Manufacturers in New Mexico Access to Leading Tech and Innovation

ALBUQUERQUE, N.M., Sept. 19, 2023 /PRNewswire/ -- The People's Ecosystem (TPE), a BIPOC women-owned cannabis conglomerate fighting for social-economic equity, today announced Toci Treatstm powered by Unlokttm from Day Three Labs (DTL), the first proven novel protein delivery technology disrupting the way edibles are developed, delivered and consumed, will hit dispensary shelves in New Mexico before the end of this year.

"As a sixth-generation survivor of the War on Drugs and a native to New Mexico, I experienced the decimation of our communities and am proud to bring edibles powered by Unlokttm home to help us all heal from that trauma," said Melanie Davis, COO, The People's Ecosystem. "Because of our government, legislature and the ingenuity of legacy operators, the regulated cannabis market in New Mexico is producing some of the most diverse, creative brands in the industry that will now have access to superior delivery technology that will set their products apart from anything on dispensary shelves today."

Toci Treats, already available in the California market, leverages Unlokttm, a pharmaceutical- grade delivery system that packs cannabis within a natural protein and shuttles the cannabis directly into the body's circulation, protecting the cannabinoids and terpenes and allowing them to be released and absorbed into the bloodstream in their entirety. With decades of pharmaceutical research and expertise behind it, Unlokttm is an alternative delivery system to nano-emulsions typically used in cannabis edibles, for a safer, cleaner, more predictable and efficient edibles experience.

"We launched Toci Treats with Unlokttm last year in California because most edibles available were made with nano-emulsions, included chemicals and surfactants or weren't transparent about the all of their ingredients," said Christine De La Rosa, CEO of The People's Ecosystem. "Through Toci Treats and as an Unlokttm manufacturing partner in this market, we are giving people an opportunity to heal with a safer alternative to alcohol and other edibles on the market, and giving edibles makers across the state access to pharma-grade technology and innovation to produce safer, better products."

In addition to Toci Treats, TPE is working with Day Three Labs to develop Toci Tabs powered by Unlokttm, a sublingual cannabis edible that melts in your mouth with an onset time of about 5 minutes, the fastest onset of any edible available today.

"We share a mission with The People's Ecosystem to ensure everyone, especially people most impacted by the War on Drugs, have access to the most innovative, highest quality cannabis products" said Josh Rubin, Co-Founder and CEO, Day Three Labs. "With Unlokttm and now with Unlokttm,  edibles manufacturers that want to overcome inconsistency in dosing and delivery technologies and address the growing demand for precisely dosed edibles with faster onset times that offer incredible new experiences, can unlock the full potential of cannabis edibles in a new, cost-effective way to enhance the consumer experience and stay competitive."

To connect with TPE for more information about manufacturing edibles with Unlokt in New Mexico, please visit https://thepeoplesecosystem.com/the-peoples-manufacturing/. For more information about Unlokttm, please visit https://daythreelabs.com/.

About The People's Ecosystem

Grounded on the intrinsic value of cannabis culture, The People's Ecosystem actively promotes equity in the cannabis industry in a way that authentically reflects the plant's diverse history. With a particular interest in BIPOC and women-led companies, TPE focuses on bringing equity and opportunity to marginalized communities by helping companies through their experience and network to canna-entrepreneurs.

About Day Three Labs

Day Three Labstm (DTL) is a cannabinoid CPG ingredient manufacturer specializing in the development and commercialization of novel cannabis product solutions. An international company with headquarters in Denver and a pharmaceutical research lab in Israel, DTL reimagines existing cannabis offerings with pharmaceutical-grade technology and innovation like Unlokttm to deliver precision and predictability to the infused product experience. Without any synthetic ingredients or surfactants, Unlokt preserves the delicate terpenes and cannabinoids in every strain, resulting in a highly functional, and very pleasurable experience that enhances the lives of consumers and patients.

SOURCE Day Three Labs


These press releases may also interest you

at 18:14
SARC (Sarcoma Alliance for Research Through Collaboration) is proud to announce the launch of the Sarcoma Centers Registry https://sarctrials.org/sarcoma-centers/, a comprehensive, global resource facilitating...

at 18:08
Genprex, Inc. ("Genprex" or the "Company") , a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced with great respect and sorrow the unexpected passing last night of...

at 18:02
It takes a unique, special kind of dedication to become a nurse. For the nurses in First Nations and Inuit communities, it takes strength, resiliency, expertise, and most importantly, heart. It takes an understanding of the complex environment of...

at 17:44
On Tuesday, May 7, 2024, The Center for Discovery® (TCFD, The Center) honored Edward C. Sweeney, TCFD Board Chair, at the 24th annual Evening of Discovery Gala. The Gala was hosted by Mo Rocca, CBS Sunday Morning Correspondent, Humorist, and Creator...

at 17:30
PT217 is Phanes' first-in-class bispecific antibody targeting DLL3 and CD47; atezolizumab (TECENTRIQ®) is Roche's anti-PD-L1 monoclonal antibodyThe clinical supply agreement will focus on evaluating PT217 in combination with atezolizumab for the...

at 17:30
Kyowa Kirin Co., Ltd. (TSE: 4151) today announced that data from the pre-clinical pharmacokinetics & efficacy study comparing ocular tissue distribution after ocular instillation of tivozanib eye drops will be presented at the upcoming Association...



News published on and distributed by: